Value of p53 and estrogen receptors immunohistochemical staining in endometrial carcinoma

Endometrial carcinoma represents the most common female genital cancer in the US. From 2006, both incidence and death rate increased by about 1% and 2% per year, respectively. The average age of woman diagnosed with endometrial carcinoma is 60, while it is uncommon in woman younger than 45. The differences in the epidemiology, presentation and biological behaviour of endometrial carcinoma suggest that there are two types of pathogenic diseases: type I endometrial carcinoma, also known as estrogen dependent or endometrioid type, and the type II, which is estrogen independent and non-endometrioid type. While type I ABSTRACT

• Publication year

  2019

• Venue

  International journal of reproduction, contraception, obstetrics and gynecology

• Publication date

  2019-11-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.18203/2320-1770.ijrcog20195339
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression

  2019cited by this paper
• Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor

  2018cited by this paper
• Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility

  2018cited by this paper
• Erratum to: Endometrial Cancer

  2017cited by this paper
• Association of the hormonal receptor status of endometrial carcinomas with the markers of tumor aggression: A comparison with similar studies in developed nations

  2017cited by this paper
• Uterine Papillary Serous Carcinoma

  2011cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).

  2010cited by this paper
• Factors associated with Type I and Type II endometrial cancer

  2010cited by this paper
• Biologic markers in endometrial cancer treatment

  2009cited by this paper
• Novel molecular profiles of endometrial cancer-new light through old windows.

  2008influential reference
• Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

  2006cited by this paper
• Worldwide burden of gynaecological cancer: the size of the problem.

  2006cited by this paper
• Large-scale gene expression studies of the endometrium: what have we learnt?

  2006cited by this paper
• The Molecular Genetics of Endometrial Cancer

  2005cited by this paper
• BRAF Mutation in Endometrial Carcinoma and Hyperplasia: Correlation with KRAS and p53 Mutations and Mismatch Repair Protein Expression

  2005cited by this paper
• The biological role of estrogen receptors α and β in cancer

  2004cited by this paper
• A significance of immunohistochemical determination of steroid receptors, cell proliferation factor Ki-67 and protein p53 in endometrial carcinoma.

  2004cited by this paper
• Apoptosis-Related Proteins and Steroid Hormone Receptors in Normal, Hyperplastic, and Neoplastic Endometrium

  2002cited by this paper
• Immunohistochemical Profile of Endometrial Adenocarcinoma: A Study of 61 Cases and Review of the Literature

  2000cited by this paper
• World Health Organization classification of tumors

  2000cited by this paper
• Prognostic factors in endometrial carcinoma.

  1999cited by this paper
• Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of Stage I endometrial carcinoma

  1999cited by this paper
• Immunohistochemical determination of estrogen and progesterone receptors and DNA flow cytometry in endometrial cancer

  1993cited by this paper
• Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody.

  1986cited by this paper
• Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

  1985cited by this paper
• Two pathogenetic types of endometrial carcinoma.

  1983cited by this paper
• Cancer,Facts and Figures about.

  year unknowncited by this paper

• Clinico-Morphological Features and Immunohistochemical Profile of a Rare Case of Three Synchronous Primary Malignancies in the Female Genital Tract

  2024influential citation
• Prognostic and clinicopathological significance of survivin in gynecological cancer

  2024cites this paper
• p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study

  2022cites this paper